Roche Holding AGRHHBY
OTC • Healthcare
$51.26
P/E
18.78
PEG
0.77
FCF Yield
—
Rev Growth YoY
-1.1% YoY
Gross Margin
71.7%
Health Score
7/10
D/E Ratio
0.94
Confidence
MEDIUM
Business Snapshot
Roche Holding AG is a global pharmaceutical giant with a diversified portfolio of prescription drugs, diagnostics, and oncology therapies. The company operates in the highly regulated drug manufacturing industry, competing against other large-cap pharma firms like Novartis, Pfizer, and Merck. With approximately $109 billion in trailing twelve-month revenue, Roche is a large-cap multinational that benefits from strong patent protections and a robust pipeline. A defining characteristic is its industry-leading position in diagnostics and targeted cancer treatments, providing a stable revenue base and regulatory moat.
Financial Health
Gross margin stands at 71.7%, down from 75.7% in the prior year, signalling some cost pressure or pricing erosion. Net margin of 13.7% reflects solid profitability, though it is partly offset by the gross margin decline...
Risk Assessment
- REVENUE DECLINATION — Revenue shrank 1.1% YoY, breaking the growth trend and signalling headwinds from patent expirations or generic erosion.
- MARGIN COMPRESSION — Gross margin fell from 75.7% to 71.7% year-over-year, indicating rising input costs or pricing pressure that could further erode profitability.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- 52-WEEK PRICING — The current price of $51.26 is 15.8% below the 52-week high of $60.85, implying the stock has not fully recovered from its recent lows....
Metric deep-dives